Invasive cell migration is a key step for cancer metastasis and involves Rho GTPase-controlled reorganization of the actin cytoskeleton. Altered Rho GTPase expression is found in various malignancies. Particularly, the closely related GTPases RhoA and RhoC are upregulated in many aggressive tumours, but specific effectors that distinguish between these two GTPases to explain mechanistic differences have not been identified. The formins are by far the largest family of Rho GTPase effectors and are characterized by the actin-nucleating formin homology 2 domain. Using siRNA-based screening against all 15 human formins, we systematically analysed their functions in 3D cell motility using three different cancer cell lines. These results reveal distinct requirements for specific formins in amoeboid versus mesenchymal invasive cell migration. Importantly, by knocking down all Rho proteins, we identified formin-like 2 (FMNL2) as a specific RhoC effector, showing selective interaction of FMNL2 with active RhoC, but not RhoA or RhoB. Functional analysis shows that RhoC regulates autoinhibition of FMNL2, whereas suppression of FMNL2 inhibits RhoC-, but not RhoA-dependent, rounded invasive cell migration. Thus, our data uncover a novel regulatory and functional interaction between RhoC and FMNL2 for modulating cell shape and invasiveness and provide mechanistic insight into RhoC-specific signalling events.
Introduction
Deregulated cell motility and invasion is a crucial initial step in metastasis, one of the features of malignant tumour cells. Invasive cell migration involves movement through tissues, dynamic interactions with the extracellular matrix, rearrangements of cell-to-cell contacts and the cytoskeleton (Sahai, 2007) . Cells use two different modes of invasion, depending on the specific signalling pathways: the mesenchymal mode that is characterized by an elongated cell shape requiring extracellular proteolysis and the single cell amoeboid mode, displaying a rounded, often bleb-associated cell morphology using actin-myosin contractility (Sahai, 2005; Fackler and Grosse, 2008) . During metastasis, tumour cells may switch between these modes of invasion depending on the activation status of specific Rho GTPases (Sanz-Moreno et al., 2008) . Hence, alterations of Rho GTPase signalling is found in many tumours and can contribute to progression and metastasis by influencing growth, oncogenic transformation, survival and cell motility (Fleming et al., 2009; Karlsson et al., 2009) .
Formins comprise by far the largest group of Rho GTPase effectors with 15 members in mammals and are characterized by the presence of a conserved actinpolymerizing formin homology 2 domain (Goode and Eck, 2007) . Formins are involved in essential cellular processes such as cytokinesis, cell polarity, cell adhesion and cell migration (Faix and Grosse, 2006) , which are frequently deregulated in malignancies. Most formins are autoinhibited by intramolecular interactions between the N-terminus and the C-terminus, whereas binding of active Rho GTPases to the N-terminal GTPase-binding domain (GBD) can relieve autoinhibition to promote actin nucleation and assembly (Faix and Grosse, 2006) . We have earlier shown that the formin Diaphanous 1 (Dia1) is essential for fibroblast wound healing as well as for amoeboid cell invasion (Goulimari et al., 2005 (Goulimari et al., , 2008 Kitzing et al., 2007) . However, very little is known about the general functions of human formins and their specific Rho GTPase regulation in cancer cell invasion.
Here, we used siRNA against all 15 human formins to systematically analyse their function during invasive cancer cell migration. To discover potential and novel endogenous Rho GTPase regulation of formins, we subsequently correlated the results with effects on Rho GTPase knock down during cell invasion. Our data identify formin-like 2 (FMNL2) as a novel and specific RhoC effector and show a biological function for FMNL2 during rounded invasive cell motility.
Formin expression in human cancer cells
To systematically analyse formin function in invasive cell migration, we used the three cancer cell lines MDA-MB-435 (Kitzing et al., 2007) , MDA-MB-231 (Wolf et al., 2003) and HT1080 (Wolf et al., 2007) to perform siRNA-based screening (Figure 1a) . When cultured in a 3D environment, MDA-MB-435 melanoma cells adopt a rounded, amoeboid morphology and MDA-MB-231 breast carcinoma cells exhibit a collective, mesenchymal morphology, whereas HT1080 fibrosarcoma cells display a more mesenchymal morphology with a mix of single cells and collective cell groups (Figure 1b) . First, we analysed the expression of all known formins in these cell lines by real-time RT-PCR. Although mRNA levels vary, the majority of formins seemed to be surprisingly widely distributed, whereas Daam2, Delphilin and Formin 2 were expressed more differentially (Figure 1c ).
Distinct requirements of formins in invasive cell migration
To dissect the requirements of formins in invasive cell migration, SMARTpool siRNA was used to silence all 15 formins in the three different cancer cell lines. (Kitzing et al., 2007; Brandt et al., 2009) . This revealed that suppression of formins differentially affects cell invasion and morphology as shown for MDA-MB-435 cells in Figure 2a and as quantified and summarized from three independently performed screening rounds for each of the three investigated cancer cell lines ( Figure 2b ). We earlier reported that Dia1 influences amoeboid invasion of MDA-MB-435 cells by a positive feedback resulting in increased ROCK-regulated myosin function (Kitzing et al., 2007) . Indeed, results from the screen confirmed that Dia1 silencing strongly inhibited MDA-MB-435 invasion. In addition, we found that silencing of Dia1 also partially inhibited mesenchymal invasion (Figures 2b and c) . Suppression of Dia2 or Dia3 displayed no inhibitory effect on invasion in all three cell lines investigated (Figure 2b ). This conflicts with an RhoC-FMNL2 interaction in invasive cell migration TM Kitzing et al earlier report for MDA-MB-231 cells (Lizarraga et al., 2009) , although this may well be accounted for by different methodologies applied to measure invasiveness. In MDA-MB-435 cells, however, suppression of Dia2 consistently accelerated amoeboid invasive migration ( Figure 2b ). Similarly, knocking down inverted formin 2 robustly promoted rounded cell motility of MDA-MB-435 cells, whereas suppressing invasion of HT1080 cells (Figure 2b) .
Interestingly, only suppression of FMNL2 specifically blocked amoeboid invasive migration of MDA-MB-435 cells (Figures 2b and c) . This result was confirmed using two additional siRNAs directed against FMNL2 (inset Figure 2b ). Of note, FMNL2 was recently shown to be overexpressed or mutated in human cancers Zhu et al., 2008) ; thus, we decided to concentrate on the functional role of FMNL2 for rounded cell invasion.
FMNL2 specifically interacts with RhoC
Next, to uncover the potential Rho GTPase regulation of FMNL2, we performed siRNA-based analyses for all human Rho proteins for MDA-MB-435 cell invasion (Supplementary Table 3 ). From this, several Rho proteins such as RhoA, RhoC, Rnd1 and Rnd3/RhoE were found to inhibit 3D motility of MDA-MB-435 by >50%.
From these results, we decided to examine the possible Rho protein interactions with the GBD of FMNL2 (Figure 3a) . To our surprise, using a fragment consisting of the GBD and the adjacent FH3, we specifically detected FMNL2 interaction with the constitutively active mutant of RhoC.V14 (Figure 3b ), while binding to the highly homologous GTPase family members RhoA and RhoB, as well as Cdc42, Rac1, Rnd1, Rnd3/RhoE or RhoJ/TCL was undetectable (Figure 3b ). Of note, RhoC has been shown to be essential for metastasis (Clark et al., 2000; Hakem et al., 2005) and the importance of RhoC for cancer cell invasion has been confirmed using RNA interference (Simpson et al., 2004; Pille et al., 2005) . However, the precise mechanism of how RhoC promotes tumour cell invasion is unclear.
RhoC differs at its N-terminus, including Switch I and Switch II regions, only in one amino acid compared with RhoA and RhoB (Wheeler and Ridley, 2004 ). This residue is Isoleucin at position 43 (I43), which lies in very close proximity to the switch I region, which has a central part in Rho GTPase effector interaction. Hence, we decided to mutate this residue to Valine as in RhoA and RhoB to determine the effects on binding to FMNL2. Interestingly, we found that RhoC.V14/V43 interacted significantly less well with the GBD of FMNL2, although residual binding was still detected (Figure 3c ). Nevertheless, this clearly indicated that I43 contributes to the binding specificity between FMNL2 and RhoC. In addition, direct binding experiments using purified Rho proteins confirmed the specificity of interaction between FMNL2 and RhoC.V14, whereas binding to RhoA.V14 was undetectable (Figure 3d ). These results show that FMNL2 interacts specifically with active RhoC and suggest that FMNL2 could be an important effector for RhoC during invasive motility.
RhoC regulates FMNL2 function
To functionally explore the RhoC FMNL2 interaction, we performed 3D.A.Luc SRF reporter gene assays, known to tightly correlate with actin polymerization (Copeland and Treisman, 2002; Grosse et al., 2003) . Expression of increasing amounts of the FMNL2 Nterminus (N-t) inhibited activation of the SRF reporter gene by the formin homology 2 domain-containing C-terminus (C-t), recapitulating the recently reported autoregulatory control of FMNL2 (Vaillant et al., 2008) (Figure 4a; Supplementary Figure 1a) . Interestingly, we observed that the N-t-dependent inhibition of FMNL2 C-t activity could be specifically relieved in a concentration-dependent manner by addition of constitutively active RhoC.V14, but not by RhoA.V14. Moreover, expression of autoinhibited full-length FMNL2 did not induce reporter activity by itself, whereas FMNL2 autoinhibition was partially and specifically relieved by expression of RhoC.V14, but not RhoA.V14 (Figure 4b ; Supplementary Figure 1b) , suggesting that activated RhoC modulates FMNL2-regulated actin dynamics. In contrast, the formin Dia1 could be activated to a similar extent by either active RhoA or RhoC (Figure 4b ; Supplementary Figure 1b) , suggesting that Dia1 can be regulated by both GTPases as reported earlier (Watanabe et al., 1999; Rose et al., 2005) .
To further investigate the FMNL2 regulation and function, MDA-MB-435 cells were transfected with control or FMNL2 siRNA and stained for F-actin. Cells silenced for FMNL2 showed fewer actin fibres and a decreased F-actin content (Figures 4c and d) , pointing towards a relevant function of FMNL2 for actin assembly in cancer cells.
Finally, to analyse whether FMNL2 is in fact required for RhoC function during invasive cell migration, we generated MEFs that stably express mRFP, mRFPRhoC or mRFP-RhoA and suppressed FMNL2 by siRNA (Supplementary Figure 1c) . Interestingly, cells expressing RhoC or RhoA displayed increased invasiveness accompanied by a rounded cell morphology as compared with mRFP expressing MEFs (Figures 4e  and f) , suggesting that they switch to amoeboid invasive behaviour under these assay conditions. Of note, when expression of FMNL2 was suppressed by siRNA, the RhoC-dependent increase in invasion was specifically blocked, whereas mRFP-or RhoA-expressing cells were not affected (Figure 4f ). These data strongly argue for a crucial and regulatory interaction between the formin FMNL2 and RhoC for invasive cell migration.
The recent discovery of new groups of actin nucleators (Chesarone et al., 2009 ) has opened the possibility for exploring the mechanisms, which lead to deregulated RhoC-FMNL2 interaction in invasive cell migration TM Kitzing et al cell motility. We describe here the first systematic investigation of the function of the largest group of actin nucleators, the formin proteins, during invasive cell migration. Very recently, mutations of FMNL2, formin 2 and formin-like 3 have been found in human glioblastoma multiforme and pancreatic cancer Parsons et al., 2008) . Moreover, it has been shown that FMNL2 is overexpressed in cancer and involved in metastasis of colorectal cancer (Zhu et al., 2008) , pointing towards a function for this formin in tumour progression.
In this study, we identify FMNL2 as a critical regulator required for amoeboid invasion downstream of RhoC, but not RhoA. Our data argue that the residue I43 adjacent to the Switch I region in RhoC contributes to the binding specificity between FMNL2 and RhoC versus RhoA and RhoB, but that this is not the only mechanism. Serine phosphorylation of RhoA could also have a function in the differential binding of FMNL2 to RhoC as described here; however, we did not detect binding of FMNL2 with the relevant RhoA phosphorylation mutants (data not shown). HEK293 cells were transfected with 5 mg of indicated plasmids and subjected to pulldown assays using GST-FMNL2-GBD. (c) HEK293 cells were transfected with RhoC.V14 or RhoC.V14/V43 and subjected to pulldown assays using GST-FMNL2-GBD. Quantifications from three independent experiments are shown on the right. (d) His 6 -tagged Rho proteins were purified using Ni-NTA agarose beads. GST-FMNL2-GBD was incubated with His-RhoC.V14 or His-RhoA.V14 and directly bound proteins were eluted and analysed by immunoblotting as indicated.
RhoC-FMNL2 interaction in invasive cell migration TM Kitzing et al
Interestingly, RhoC was earlier shown to be essential for metastasis using RhoC-deficient mice (Hakem et al., 2005) . We report here that RhoC is required for amoeboid invasion and this is mediated through FMNL2. Thus, one may speculate that the rounded and rapid single cancer cell motility may be more efficient in seeding distant metastasis than the collective, mesenchymal mode of invasion. 
Our results show that formin proteins may have specific and distinct functions in cancer cell invasion. Importantly, these results identify FMNL2 as a novel, specific and regulated RhoC effector and show that FMNL2 function is important for RhoC-dependent cell motility. Further investigation of the regulation of formin proteins and the pathways through which they act is required to better understand their precise biological functions in vivo and to determine whether some of them may serve as potential future drug targets.
Materials and methods
Plasmids and materials FMNL2 GBD (aa 23-276) and FMNL2 GBD þ FH3 (aa 23-484) were isolated by PCR amplification from MDA-MB-435 cDNA using the following primers: forward 5 0 -GGTG GAATTCTAGACTCCCTGCCGATGCCAGAGCCAGGTG, reverse 5 0 -AAGCTTGAGCTCGAGTCGACAAACGGCTG CCAACAGTTCTAAG and reverse 5 0 -AAGCTTGAGCTCG AGTCGCTGAATTTTAATGGTC-CCTTG, respectively. The PCR products were then cloned into the bacterial expression vector pGEX-KG (GE Healthcare, Munich, Germany). Fmnl2 N-t (aa 23-484) and Fmnl2 C-t (aa 485-1092) were isolated by PCR amplification from mouse cDNA using the following primers: forward 5 0 -GGCTCGAGATCGATCTGCCGATGC CAGAGCCAGGTG, reverse 5 0 -TC-TAGACTAGTACTGA ATTTTAATGGTCCCTTG and forward 5 0 -GCGCGCAT CGATAAGAAAGGGGATGGGGAT, reverse 5 0 -TCTAGA CTAGTCATTGTTATTTCGGCACC, respectively. PCR products were then cloned into EF-HA and EF-myc expression vectors. Flag-FMNL2 is described in Vaillant et al. (2008) . HA-RhoC.V14 was a gift from O.T. Fackler (University of Heidelberg). EF-myc RhoA.V14, EF-myc Rac1.V12, EF-myc Cdc42.V12 and EF-myc RhoC are described in Hill et al. (1995) . RhoB Q63L is described in Mellor et al. (1998) . HARhoC.V14/V43 as well as 6xHis-RhoA.V14 and RhoC.V14 were generated using standard PCR-based procedures. a-tubulin and a-GST antibody were from Sigma, a-RhoC and a-RhoA from Cell Signaling and a-FMNL2 from Abnova.
Cell culture and siRNA transfection MDA-MB-435 and MDA-MB-231 cell lines were maintained as described earlier (Brandt et al., 2009) . mRFP, mRFP-RhoA and mRFP-RhoC stably expressing MEF cells were grown in DMEM containing 10% foetal bovine serum supplemented with Hygromycin (100 mg/ml). SMARTpool siRNA was obtained from Dharmacon (http://www.dharmacon.com). Catalogue numbers and target GeneIDs are listed in Supplementary Table 1 . siRNAs against mouse Fmnl2 5 0 -AUGUGG ACGAAUUUGAAGAUU, GUGCUAAGAGAACUGGAA AUU and against human FMNL2 #1 5 0 -GUGG-UAGCAGG UAACUCUGUU and #2 GCCUGAACAACAAGAAUCC UU were from IBA. Rho GTPase SMARTpools were kindly provided by E Sahai (Cancer Research UK) and have been described earlier (Pinner and Sahai, 2008) . A total of 100 nM siRNA oligos were transfected using magnet-assisted transfection (MATra) reagent according to the manufacturer's (IBA, Go¨ttingen, Germany) instructions; 48-72 h after siRNA transfection, cells were used for subsequent analysis.
Invasion assays, immunostaining and confocal microscopy Three-dimensional invasion assays were performed as described using growth factor-reduced Matrigel (Kitzing et al., 2007) . Upper chambers of Transwell inserts were coated with Matrigel and incubated for 60 min at 37 1C for polymerization. Transwell inserts were inverted and cells were seeded (10 000 per insert) and left to adhere for 3 h before inserts were re-inverted. The lower chambers were filled with medium containing 0.5% foetal bovine serum and upper chambers containing the Matrigel were filled with medium containing 20% foetal bovine serum. Invasion assays were incubated for 48 h, then fixed and stained using DAPI and rhodamine phalloidin (Molecular Probes, Karlsruhe, Germany) or Alexa488 phalloidin (Molecular Probes) before confocal analysis (Leica TCS SP2). Three independently performed siRNA-based invasion screens were carried out in duplicates (32 Transwells each round). For each single Transwell insert five randomly chosen imaging fields were analysed using laser-scanning microscopy and confocal stacks over 100 mm (z-axis) were acquired. Quantifications of the numbers of non-invaded versus invaded cells were performed for images from confocal stacks using ImageJ Analyze Particles application. For immunostaining of MDA-MB-435 cells in 2D, samples were imaged using a Leica DMIRE2 microscope and fluorescence intensities of whole cells were quantified using ImageJ.
Real-time reverse transcription PCR Total RNA from cells was extracted using TRIZOL reagent (Invitrogen, Karlsruhe, Germany) according to manufacturer's instruction. RNA was reverse transcribed using Revert Aid M-MuLV reverse transcriptase (Fermentas, St Leon-Rot, Germany) and quantified using SYBR green (Bio-Rad, Munich, Germany). The primers used for reverse transcription PCR are listed in Supplementary Table 2. GST-pulldown, direct binding and luciferase assays GST-pulldown assays for Rho GTPase interactions were modified based on an earlier described method (Ji et al., 2008) . Briefly, 1 mM purified GST-fusion protein was coupled to Glutathione Sepharose 4B beads (GE Healthcare) in lysis buffer (10 mM HEPES at pH 7.5, 150 mM NaCl, 10 mM 2-mercaptoethanol, 0.05% Tween 20) containing EDTA-free protease inhibitor cocktail (Roche, Mannheim, Germany). HEK293 cells transfected with indicated myc-or HA-tagged Rho proteins were lysed and incubated with the pre-coupled fusion protein for 1 h at 4 1C. For direct binding, 1 mg of purified His-RhoC.V14, HisRhoA.V14 or GST-FMNL2-GBD were incubated with Glutathione Sepharose 4B in incubation buffer (20 mM Tris, 100 mM NaCl, 0.1% Triton X-100, pH 7.2) for 30 min at 4 1C, beads were washed three times and subjected to western analysis. Reporter gene assays were performed as described in Grosse et al. (2003) .
